Evolve Biologics
Chris Carr has a strong background in finance, particularly in the biopharmaceutical industry. Chris currently serves as the Chief Financial Officer for Evolve Biologics since 2022. Prior to that, they held the same position at AEON Biopharma, Inc. from 2019 to 2022 and at Dendreon from 2017 to 2019. Additionally, they have experience working at Abbott as the Controller, Greater China from 2014 to 2016 and as the Controller, Commercial Finance from 2004 to 2014. Earlier in their career, they worked as the Director of Finance at PerkinElmer from 2002 to 2004 and at Genzyme as the Director of Finance and Controller GZMO from 1990 to 2000.
Chris Carr attended Boston College from 1988 to 1992, where they obtained a Bachelor of Science degree in Economics & Finance.
This person is not in any offices
Evolve Biologics
Evolve Biologics Inc. offers the development and commercialization of plasma-derived therapeutics, using its proprietary PlasmaCap EBA purification technology to more efficiently and effectively meet growing global patient demand for these life-saving products. The Company is currently in the process of commercializing an exciting and innovativeportfolio of product candidates, including IVIG (intravenous immunoglobulin) and Albumin (human serum albumin), both of which are in advanced stages of regulatory approval in the US (FDA) and Canada (Health Canada).